Researchers discover genes that suppress lymphoma in mice

RNA is making a comeback. For years researchers all-but-ignored RNA, assuming much of it was junk or served such simple purpose that it wasn't worth researching. That's all changing.

Researchers from New York's Cold Spring Harbor Laboratory suppressed the activity of hundreds of candidate tumor suppressing genes in mice using a technology called RNA interference. What they found was at least 10 genes that, once switched off, caused a rapid acceleration of the development of lymphomas in the mice. Furthermore, there seemed to be some specificity related t o these genes in their context, meaning that tumor suppressing genes for lymphoma don't suppress tumors in other cancers.

What it all may lead to is better immunotherapy drugs but also the possibility that some such drugs might help suppress one gene's ability to promote, say, a lung tumor, but wind up encouraging that same gene to promote the development of, say, lymphoma.

Typical. But did you expect anything less from cancer? Me neither.

The researchers published their findings in the journal Cancer Cell.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap